Get the Stockscreener App
21.98
3.64%
-0.83
After Hours:
21.98
Celldex Therapeutics Inc stock is traded at $21.98, with a volume of 783.40K.
It is down -3.64% in the last 24 hours and up +8.01% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$22.81
Open:
$22.66
24h Volume:
783.40K
Relative Volume:
0.79
Market Cap:
$1.46B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-8.5194
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
-5.34%
1M Performance:
+8.01%
6M Performance:
-10.25%
1Y Performance:
-42.32%
1-Day Range:
$21.73
$23.02
1-Week Range:
$21.57
$23.50
52-Week Range:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
21.98 | 1.51B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight - PR Newswire
What are Celldex Therapeutics Inc. company’s key revenue driversSmart Portfolio Planner For Beginners - jammulinksnews.com
Visual analytics tools that track Celldex Therapeutics Inc. performanceSector-Wise Equity Performance Trend Forecast - Newser
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.Market Sentiment Tracker with Smart Alerts - Newser
Will Celldex Therapeutics Inc. continue its uptrendChart Driven Entry Timing for Swing Trades - Newser
Is Celldex Therapeutics Inc. stock a good hedge against inflationFree Consistent Gain Investment Strategies - Newser
Why Celldex Therapeutics Inc. stock attracts strong analyst attentionHigh Accuracy Alerts for ROI Traders Detected - metal.it
Published on: 2025-07-30 04:46:21 - Newser
How Celldex Therapeutics Inc. stock performs during market volatilityLow Drawdown Stock Screener with Analysis - Newser
Top chart patterns to watch in Celldex Therapeutics Inc.Real Time Screener for Growth Trades - Newser
What to expect from Celldex Therapeutics Inc. in the next 30 daysInstitutional Holding Behavior Pattern Analysis - Newser
Will Celldex Therapeutics Inc. Recover After Recent DeclineMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Celldex Therapeutics Inc. Attempts Reversal From Key SupportEarly Breakout Entry Point Notifications Sent - metal.it
Sectors Driving Future Growth for Celldex Therapeutics Inc. StockTechnical Trade Plan with Entry Checklist - Newser
Published on: 2025-07-28 23:24:39 - metal.it
How many analysts rate Celldex Therapeutics Inc. as a “Buy”Build a diversified portfolio for sustainable growth - jammulinksnews.com
How does Celldex Therapeutics Inc. compare to its industry peersPowerful growth strategies - jammulinksnews.com
What are analysts’ price targets for Celldex Therapeutics Inc. in the next 12 monthsUnlock your trading potential today - jammulinksnews.com
Is Celldex Therapeutics Inc. a growth stock or a value stockInvest confidently with daily market forecasts - jammulinksnews.com
Why is Celldex Therapeutics Inc. stock attracting strong analyst attentionGet real-time alerts on high-potential stocks - jammulinksnews.com
What is the dividend policy of Celldex Therapeutics Inc. stockGet high-impact stock recommendations now - jammulinksnews.com
Celldex Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Stock Market Knowledge Sharing - Newser
How strong is Celldex Therapeutics Inc. company’s balance sheetUnlock expert stock analysis and alerts - jammulinksnews.com
How Resilient Is Celldex Therapeutics Inc. Stock During Economic DownturnsStrong Return Daily Alerts - Newser
Celldex Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What drives Celldex Therapeutics Inc. stock priceFree Investment Risk Control - PrintWeekIndia
What analysts say about Celldex Therapeutics Inc. stockHigh-yield market plays - PrintWeekIndia
Is Celldex Therapeutics Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):